Search Results - "Makhlouf, Amal"

Refine Results
  1. 1

    Improved vaginal retention and enhanced antifungal activity of miconazole microsponges gel: Formulation development and in vivo therapeutic efficacy in rats by Salah, Salwa, Awad, Ghada E.A., Makhlouf, Amal I.A.

    “…Traditional azole antifungal formulations suffer from poor retention in the vaginal cavity, irritation and burning of the vaginal area. In the present work, we…”
    Get full text
    Journal Article
  2. 2

    Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study by Naguib, Marianne J., Makhlouf, Amal I. A.

    Published in Drug delivery (01-01-2021)
    “…Flibanserin (FLB) was approved by FDA for the treatment of pre-menopausal female hypoactive sexual desire disorder (HSDD). FLB suffers from low oral…”
    Get full text
    Journal Article
  3. 3

    Implementing polymeric pseudorotaxanes for boosting corneal permeability and antiaspergillus activity of tolnaftate: formulation development, statistical optimization, ex vivo permeation and in vivo assessment by Aziz, Diana, Mohamed, Sally, Tayel, Saadia, Makhlouf, Amal

    Published in Drug delivery (31-12-2022)
    “…Fungal keratitis (FK) is a devastating ocular disease that can cause corneal opacity and blindness if not treated effectively. Tolnaftate (TOL) is a selective…”
    Get full text
    Journal Article
  4. 4

    Enhanced Oral Absorption of Amisulpride Via a Nanostructured Lipid Carrier-Based Capsules: Development, Optimization Applying the Desirability Function Approach and In Vivo Pharmacokinetic Study by El Assasy, Abd El-Halim I., Younes, Niha F., Makhlouf, Amal I. A.

    Published in AAPS PharmSciTech (01-02-2019)
    “…Amisulpride (AMS), a second generation antipsychotic, suffers from low oral bioavailability (48%). This might be due to its pH-dependent solubility or being a…”
    Get full text
    Journal Article
  5. 5

    Nano Milk Protein-Mucilage Complexes: Characterization and Anticancer Effect by El-Maksoud, Ahmed Ali Abd, Makhlouf, Amal I A, Altemimi, Ammar B, El-Ghany, Ismail H Abd, Nassrallah, Amr, Cacciola, Francesco, Abedelmaksoud, Tarek Gamal

    Published in Molecules (Basel, Switzerland) (21-10-2021)
    “…The anticancer activity of natural compounds has recently attracted multidisciplinary research. In this study, the complexation of milk proteins (MP) with…”
    Get full text
    Journal Article
  6. 6

    Relieving postherpetic neuralgia pain via gabapentin-loaded bigels as an auspicious topical drug delivery system by Abd-Elsalam, Wessam H., Al-Mahallawi, Abdulaziz Mohsen, Makhlouf, Amal

    Published in Daru (08-10-2024)
    “…Background Over the past decades, a substantial portion of the population worldwide has been infected with varicella zoster and most cases developed shingles…”
    Get full text
    Journal Article
  7. 7

    Microenvironmental pH-modified Amisulpride-Labrasol matrix tablets: development, optimization and in vivo pharmacokinetic study by Younes, Nihal Farid, El Assasy, Abd El-Halim I., Makhlouf, Amal I.A.

    Published in Drug delivery and translational research (01-02-2021)
    “…Amisulpride (AMS) is atypical antipsychotic with a weak basic nature (pKa 9.37), which results in low solubility in the high pH of the intestine. It is also…”
    Get full text
    Journal Article
  8. 8

    Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer by Solomon, Viswas Raja, Alizadeh, Elahe, Bernhard, Wendy, Makhlouf, Amal, Hartimath, Siddesh V., Hill, Wayne, El-Sayed, Ayman, Barreto, Kris, Geyer, Clarence Ronald, Fonge, Humphrey

    Published in Scientific reports (29-10-2020)
    “…Overexpression of insulin growth factor receptor type 1 (IGF-1R) is observed in many cancers. Antibody drug conjugates (ADCs) with PEGylated maytansine (PEG 6…”
    Get full text
    Journal Article
  9. 9

    Enhanced Ocular Anti-Aspergillus Activity of Tolnaftate Employing Novel Cosolvent-Modified Spanlastics: Formulation, Statistical Optimization, Kill Kinetics, Ex Vivo Trans-Corneal Permeation, In Vivo Histopathological and Susceptibility Study by Aziz, Diana, Mohamed, Sally A, Tayel, Saadia, Makhlouf, Amal

    Published in Pharmaceutics (01-08-2022)
    “…Tolnaftate (TOL) is a thiocarbamate fungicidal drug used topically in the form of creams and ointments. No ocular formulations of TOL are available for fungal…”
    Get full text
    Journal Article
  10. 10

    Nose to brain delivery of mirtazapine via lipid nanocapsules: Preparation, statistical optimization, radiolabeling, in vivo biodistribution and pharmacokinetic study by Ibrahim, Mennatullah M., Basalious, Emad B., El-Nabarawi, Mohamed A., Makhlouf, Amal IA, Sayyed, Marwa Eid, Ibrahim, Ismail Taha

    Published in Drug delivery and translational research (01-09-2024)
    “…Mirtazapine (MZPc) is an antidepressant drug which is approved by the FDA. It has low bioavailability, which is only 50%, in spite of its rapid absorption when…”
    Get full text
    Journal Article
  11. 11

    Design, Optimization, and Evaluation of a Novel Metronidazole-Loaded Gastro-Retentive pH-Sensitive Hydrogel by El-Mahrouk, Galal M., Aboul-Einien, Mona H., Makhlouf, Amal I.

    Published in AAPS PharmSciTech (01-12-2016)
    “…ABSTRACT Floating pH-sensitive chitosan hydrogels containing metronidazole were developed for the eradication of Helicobacter pylori from the stomach…”
    Get full text
    Journal Article
  12. 12

    Correction to: Enhanced Oral Absorption of Amisulpride Via a Nanostructured Lipid Carrier-Based Capsules: Development, Optimization Applying the Desirability Function Approach and In Vivo Pharmacokinetic Study by El Assasy, Abd El-Halim I., Younes, Nihal Farid, Makhlouf, Amal I. A.

    Published in AAPS PharmSciTech (25-02-2019)
    “…The second author’s name was incorrectly published as “Niha F. Younes”. The correct name is “Nihal Farid Younes” as shown above in the list of authors…”
    Get full text
    Journal Article
  13. 13

    Hair regrowth boosting via minoxidil cubosomes: Formulation development, in vivo hair regrowth evaluation, histopathological examination and confocal laser microscopy imaging by Makhlouf, Amal, Elnawawy, Tayseer

    Published in International journal of pharmaceutics (05-03-2023)
    “…[Display omitted] Minoxidil has been used as an effective and cost-efficient topical treatment for androgenic alopecia. However, due to its poor water…”
    Get full text
    Journal Article
  14. 14

    Flexosomes as a promising nanoplatform for enhancing tolnaftate ocular delivery: Formulation, in vitro characterization, statistical optimization, ex vivo and microbial in vivo studies by Aziz, Diana, Mohamed, Sally, Tayel, Saadia, Makhlouf, Amal

    Published in International journal of pharmaceutics (05-11-2023)
    “…[Display omitted] The eye is a complex organ with a unique physiology and anatomy. Using novel nanosystems is expected to enhance ocular drug permeation and…”
    Get full text
    Journal Article
  15. 15

    Adoption of polymeric micelles to enhance the oral bioavailability of dexibuprofen: formulation, in-vitro evaluation and in-vivo pharmacokinetic study in healthy human volunteers by Abdelbary, Ghada, Makhlouf, Amal

    Published in Pharmaceutical development and technology (01-09-2014)
    “…Abstract This work aimed to incorporate Dexibuprofen (DXI), the pharmacologically active and more potent form of ibuprofen, into polymeric micelles based…”
    Get full text
    Journal Article
  16. 16

    sup 89^Zr-labeled domain II specific anti-EGFR ScFv-Fc antibody fragment for imaging and monitoring of response to anti-EGFR treatment by PET by Alizadeh, Elahe, Solomon, Viswas Raja, Zuluaga, Carolina, Bernhard, Wendy, Makhlouf, Amal, Barreto, Kris, Geyer, Clarence, Fonge, Humphrey

    Published in The Journal of nuclear medicine (1978) (01-05-2018)
    “…Objectives: Epidermal growth factor receptor I (EGFR) is overexpressed in multiple cancers where it confers enhanced proliferation and resistance to targeted…”
    Get full text
    Journal Article
  17. 17

    89Zr-labeled domain II specific anti-EGFR ScFv-Fc antibody fragment for imaging and monitoring of response to anti-EGFR treatment by PET by Alizadeh, Elahe, Solomon, Viswas Raja, Zuluaga, Carolina, Bernhard, Wendy, Makhlouf, Amal, Barreto, Kris, Geyer, Clarence, Fonge, Humphrey

    Published in The Journal of nuclear medicine (1978) (01-05-2018)
    “…Objectives: Epidermal growth factor receptor I (EGFR) is overexpressed in multiple cancers where it confers enhanced proliferation and resistance to targeted…”
    Get full text
    Journal Article
  18. 18
  19. 19
  20. 20

    Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft by Hartimath, Siddesh V, El-Sayed, Ayman, Makhlouf, Amal, Bernhard, Wendy, Gonzalez, Carolina, Hill, Wayne, Parada, Angel Casaco, Barreto, Kris, Geyer, Clarence Ronald, Fonge, Humphrey

    Published in Oncotarget (01-02-2019)
    “…Nimotuzumab is a humanized anti-epidermal growth factor receptor I (EGFR) monoclonal antibody. We have developed antibody drug conjugates (ADCs) with…”
    Get full text
    Journal Article